Recent Finacing
Recent Raise
Artiva develops allogeneic off-the-shelf NK cell and CAR-NK therapies, operating a manufacturing-first platform for large-scale expansion, cryopreservation, NK-specific gene editing, and CAR-NK engineering (AB-101/201/202).
